Sporos BioDiscovery

Sporos BioDiscovery is a biotechnology R&D company with a diversified pipeline of multiple small-molecule precision oncology therapeutic projects under development, including its lead candidate SPR1-0117, a next-generation TEAD inhibitor program. Sporos BioDiscovery, Inc. is a wholly-owned subsidiary of Sporos Bioventures, LLC, a private biotechnology company focused on transforming the oncology drug development process.